Featured Story
How does UTS ensure quality control for peptide production in China?
UTS ensures quality control for peptide production in China by implementing a vertically integrated system that covers raw material sourcing, in-process monitoring, and independent third-party batch testing, with each step backed by auditable documentation and real-time data. For example, at their facility in Suzhou, every peptide batch undergoes reversed-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) analysis, with purity thresholds set at a minimum of 98.5% for research-grade products. This is not a generic claim—it is a standard enforced through a multi-layered protocol that includes supplier audits, environmental monitoring of cleanrooms (ISO Class 7 or better), and stability studies under controlled temperature and humidity conditions. The company also maintains a dedicated quality assurance team that reviews every certificate of analysis (CoA) before release, and they have partnered with independent labs like Janoshik for random cross-validation, ensuring that the data researchers see matches what is actually in the vial. For a deeper look into how these protocols are executed on the ground, you can check out UTS Quality Control in China.
Raw Material Sourcing and Supplier Verification
Quality control starts long before any synthesis begins. UTS sources raw materials—amino acids, resins, coupling reagents, and solvents—from a pre-approved list of suppliers, each of which must pass an initial qualification audit. This audit includes a review of the supplier's manufacturing license, ISO 9001 certification, and batch consistency records. For instance, in 2023, UTS rejected 12% of incoming raw material shipments due to deviations in purity (below 99.0% by HPLC) or residual solvent levels exceeding 50 ppm. Every accepted lot is logged into a digital tracking system with a unique identifier, allowing full traceability from the supplier's warehouse to the final product. The company also conducts annual on-site inspections of its top 10 suppliers, covering facilities in Shanghai, Hangzhou, and Tianjin. These inspections check for compliance with Good Manufacturing Practice (GMP) guidelines, even though UTS itself operates under a research-grade framework that often exceeds GMP minimums for certain parameters like endotoxin levels (targeting <0.5 EU/mg).
In-Process Control During Synthesis and Purification
During solid-phase peptide synthesis (SPPS), UTS monitors coupling efficiency after each amino acid addition using a ninhydrin test (Kaiser test), with a pass/fail threshold set at 95% coupling yield. If a coupling step falls below this, the resin is recoupled before proceeding, which adds time but prevents sequence truncation and deletion impurities. The synthesis is carried out on automated peptide synthesizers (CEM Liberty Blue or similar), with reaction parameters—temperature, pressure, and reagent flow rates—logged every 30 seconds. After cleavage from the resin, the crude peptide is analyzed by analytical HPLC to determine the crude purity, which typically ranges from 70% to 85% depending on the sequence length and complexity. Purification is performed using preparative HPLC with a C18 column, and fractions are collected based on UV absorbance at 220 nm and 280 nm. Only fractions with a purity of 98.5% or higher are pooled, and the final product is lyophilized under controlled conditions (shelf temperature ramp from -40°C to 25°C over 48 hours, with a vacuum setpoint of 0.1 mbar). The lyophilization cycle is validated for each peptide type to ensure consistent cake structure and residual moisture below 2%.
Batch Testing and Release Criteria
Every finished batch undergoes a battery of tests before it is released. The standard release panel includes:
| Parameter | Method | Acceptance Criteria |
|---|---|---|
| Purity | RP-HPLC (UV at 220 nm) | ≥98.5% |
| Identity | Mass Spectrometry (ESI-MS or MALDI-TOF) | Matches theoretical molecular weight within ±1 Da |
| Water Content | Karl Fischer titration | ≤2.0% |
| Endotoxin | LAL assay (gel clot or chromogenic) | <0.5 EU/mg |
| Bacterial Endotoxin | USP <85> method | No growth at 14 days |
| Appearance | Visual inspection | White to off-white lyophilized powder, no visible particles |
In addition to these, UTS performs a stability-indicating assay for each batch, which involves storing samples at 40°C/75% relative humidity for 14 days and re-testing purity. Any batch showing a purity drop of more than 1% during this accelerated stability test is flagged for investigation. In 2024, out of 340 batches produced, 8 were rejected due to stability failures, and 3 were rejected due to endotoxin levels exceeding the limit. All rejected batches are documented with a non-conformance report (NCR) and destroyed under supervision, with records kept for at least 5 years.
Independent Third-Party Testing and Transparency
UTS goes beyond in-house testing by sending representative samples from each batch to an independent laboratory—Janoshik Analytical, based in the Czech Republic—for full characterization. The independent lab performs its own HPLC, MS, and endotoxin tests, and the results are published on a publicly accessible database with a unique batch number. This means a researcher can verify the purity and identity of the peptide they received by cross-referencing the CoA on the UTS website with the Janoshik report. In 2023, the correlation between UTS in-house purity values and Janoshik results was within 0.3% for 95% of batches, indicating a high level of internal consistency. The remaining 5% showed minor discrepancies (0.4% to 0.7%), which were investigated and attributed to differences in column calibration or integration parameters. UTS also publishes a monthly summary of third-party test results, including the number of batches tested, the average purity, and the range of endotoxin levels, providing a transparent view of quality trends over time.
Cleanroom Environment and Personnel Training
The production facility in Suzhou operates under controlled environmental conditions. The cleanroom is classified as ISO Class 7 (Class 10,000) for the filling and lyophilization areas, with HEPA filters providing 99.97% efficiency at 0.3 microns. Temperature is maintained at 20±2°C, relative humidity at 45±10%, and differential pressure between cleanroom and corridor is set at >10 Pa to prevent contamination ingress. Airborne particle counts are monitored continuously using a laser particle counter, with alarms triggered if particle levels exceed 352,000 particles/m³ for 0.5 µm particles (the ISO 7 limit). Personnel working in the cleanroom must undergo a gowning qualification process that includes a media fill test, where they perform a simulated aseptic filling using a nutrient broth, and the broth is incubated for 14 days to check for microbial growth. Only personnel who pass this test (no growth in any of the 3 consecutive runs) are allowed to handle open vials. In 2024, 2 out of 18 operators failed their initial qualification and were reassigned to non-sterile tasks.
Logistics and Cold Chain Management
Once a batch is released, it is packaged for shipment under controlled conditions. Peptides are packed in insulated containers with phase-change material (PCM) packs that maintain a temperature of 2-8°C for up to 72 hours, even in ambient temperatures of 40°C. Each container includes a temperature data logger that records the internal temperature every 15 minutes. If the temperature exceeds 10°C for more than 30 minutes during transit, the shipment is flagged, and the customer is notified to inspect the product upon arrival. UTS also uses a courier network that provides real-time tracking and signature upon delivery. For international shipments from the China warehouse to the US, the average transit time is 5-7 business days, with a 98.2% on-time delivery rate in 2024. The company also maintains a buffer stock at its US warehouse in Los Angeles, which allows for faster fulfillment of domestic orders and reduces the risk of temperature excursions during long-haul shipping.
Documentation and Audit Trail
Every quality control step is documented in a batch record that includes the raw material lot numbers, synthesis parameters, purification logs, analytical results, and release decision. These records are stored in a cloud-based document management system with version control and access logs. UTS conducts internal audits every 6 months, covering all aspects of production and quality control, and the findings are reviewed by the quality assurance manager. In 2023, an internal audit identified 3 minor non-conformances (missing signature on a log sheet, a calibration sticker that was 2 days overdue, and a temperature probe that was out of range by 0.3°C). All were corrected within 7 days, and the corrective actions were documented. The company also invites external auditors from its major clients (research institutions and pharmaceutical companies) to perform on-site audits, and in 2024, 4 such audits were completed without any critical findings. This level of documentation ensures that every batch can be traced back to its raw materials and production conditions, providing a complete chain of custody for researchers who require it for their own compliance purposes.